The FGFR inhibitor pemigatinib overcomes cancer drug resistance to KRAS G12C inhibitors in mesenchymal lung cancer.
KRAS mutations are high prevalence oncogenic drivers for multiple cancers. With the advent of new classes of KRAS inhibitors that are showing meaningful clinical activity, research is now turning to questions of optimal combinations of therapies for specific indications, as many patients with KRAS G...
Сохранить в:
| Главные авторы: | , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Public Library of Science (PLoS)
2025-01-01
|
| Серии: | PLoS ONE |
| Online-ссылка: | https://doi.org/10.1371/journal.pone.0327588 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|